Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer

Charlotte Manogue, Elisa Ledet, Achuta Kumar Guddati, Brian Lewis, Oliver Sartor

Research output: Contribution to journalArticle

Abstract

Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m 2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5-FU therapy. We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.

Original languageEnglish (US)
Pages (from-to)383-385
Number of pages3
JournalOncologist
Volume23
Issue number3
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Fluorouracil
Folic Acid Antagonists
Androgens
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer. / Manogue, Charlotte; Ledet, Elisa; Guddati, Achuta Kumar; Lewis, Brian; Sartor, Oliver.

In: Oncologist, Vol. 23, No. 3, 01.03.2018, p. 383-385.

Research output: Contribution to journalArticle

Manogue, Charlotte ; Ledet, Elisa ; Guddati, Achuta Kumar ; Lewis, Brian ; Sartor, Oliver. / Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer. In: Oncologist. 2018 ; Vol. 23, No. 3. pp. 383-385.
@article{4814bac594064a86930658041c84fe84,
title = "Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer",
abstract = "Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m 2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5-FU therapy. We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.",
author = "Charlotte Manogue and Elisa Ledet and Guddati, {Achuta Kumar} and Brian Lewis and Oliver Sartor",
year = "2018",
month = "3",
day = "1",
doi = "10.1634/theoncologist.2017-0450",
language = "English (US)",
volume = "23",
pages = "383--385",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer

AU - Manogue, Charlotte

AU - Ledet, Elisa

AU - Guddati, Achuta Kumar

AU - Lewis, Brian

AU - Sartor, Oliver

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m 2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5-FU therapy. We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.

AB - Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m 2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5-FU therapy. We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.

UR - http://www.scopus.com/inward/record.url?scp=85043395165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043395165&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0450

DO - 10.1634/theoncologist.2017-0450

M3 - Article

VL - 23

SP - 383

EP - 385

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -